Hapytab Tablet (Extended Release)
by SK+F
৳10.00
Ziska Pharmaceuticals Limited
Serotonergic reuptake inhibitor (SNRI) Nevola 50mg ER Tablet is used to treat major depressive disorder (MDD). For adults with major depressive disorder diagnosed according to DSM IV criteria, Nevola 50mg ER Tablet has been shown to be effective in four short-term (eight-week placebo-controlled studies) and two maintenance studies.
Serotonergic reuptake inhibitor (SNRI) desvenlafaxine is used to treat major depressive disorder (MDD). For adults with major depressive disorder diagnosed according to DSM IV criteria, Desvenlafaxine has been shown to be effective in four short-term (eight-week placebo-controlled studies) and two maintenance studies.
Desvenlafaxine is venlafaxine's primary active metabolite. However, the specific process is uncertain, but it is assumed to be linked to the potentiation of serotonin and norepinephrine in the CNS, through suppression of their reuptake.
The recommended dose for Desvenlafaxine is 50 mg once daily, with or without food. The 50 mg dose is both a starting dose and the therapeutic dose. Desvenlafaxine should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.
In clinical studies, doses of 10 mg to 400 mg per day were studied. In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses.
The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms
With aspirin and other NSAIDs, warfarin, and other anticoagulants, there is an increased risk of bleeding
Within 14 days after discontinuation of MAOIs or concurrent use (e.g. linezolid, IV methylene blue). The MAOI should be started at least 7 days after desvenlafaxine has been stopped.
A suicidal ideation or behavior, hypertension (HTN), mydriasis, seizure disorder, hyponatraemia, interstitial lung disease and eosinophilic pneumonia; nausea and dizziness; insomnia; hyperhidrosis; constipation; somnolence; a decreased appetite and anxiety; and sexual dysfunction disorders in males (e.g. anorgasmia, decreased libido, abnormal orgasm, delayed ejaculation, erectile dysfunction, ejaculation disorder, ejaculation failure, sexual dysfunction).
Categorization of Pregnancy: C In either case, research in animals have shown harmful effects on the foetus (teratogenic, embryocidal, or other) and there are no controlled studies in women, or there are no studies in women and animals. Pregnant women should only be given drugs if the benefits outweigh the risks.
Presence of high blood pressure, elevated intraocular pressure, or mania or hypomania in the patient's own family, as well as CV, cerebrovascular, and lipid metabolic abnormalities; seizure disorder. It's best to stay away from sudden changes in your schedule Renal and moderate to severe liver dysfunction. Expectancy and breast-feeding.
Serotonin-norepinephrine reuptake inhibitor (SNRI)
Store between 20-25° C.